In August 2023, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed a worldwide licence with the Spanish National Research Council (CSIC) for a vaccine candidate based on the MVA vector platform, a highly attenuated Modified Vaccinia virus Ankara (MVA) vector that has been engineered to express a prefusion-stabilized human codon-optimized full-length SARS-CoV-2 spike (S) protein.

MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for this technology by submitting an e-mail to  providing as much detail as possible as to what the developer intends to do with a sublicence.

Key Features
Aim of the Licence To facilitate the manufacture and commercialisation of COVID-19 vaccine around the world.
Products Any product that is covered by the Patents or uses the know-how or material.
Know‐how CSIC to provide all necessary know-how and materials (including the premaster virus seed for MVA-CoV2-S(3P) and unmodified derivatives) to the licensees.

The licence does not include any Know-How held by Biofabri.

Field of use COVID-19 vaccine
Territory Worldwide
Scope of the grant Non-exclusive right to grant sublicences to develop the licensed patents/know-how/material into licensed products, and to commercialise licensed products.
  • royalty-free for low and middle-income countries.
  • 5% for high-income countries, where there is a Patent granted and in force.
  • 5% for high-income countries, where no Patent but if the licensee has used the know-how or material.
Country List